MASS syndrome

MASS syndrome is a genetic disorder stemming from a dysfunction in the body's connective tissue, primarily linked to mutations in the FBN1 gene. This gene encodes fibrillin-1, a large glycoprotein essential for the formation of elastic fibers and microfibrils in the extracellular matrix. Fibrillin-1 acts as a scaffold, enabling the assembly of microfibrils, which are crucial for the elasticity and tensile strength of various tissues.

When fibrillin-1 is defective due to FBN1 mutations, microfibril assembly is impaired, leading to compromised tissue integrity. This manifests as a reduced ability of tissues like ligaments, blood vessels, and skin to stretch and recoil appropriately, underpinning the diverse clinical features observed in MASS syndrome.

The acronym MASS syndrome encapsulates key diagnostic features: Mitral valve prolapse (MVP), Aortic root diameter at the upper limits of normal for body size, Striae distensae (stretch marks), and Skeletal conditions similar to Marfan syndrome. MVP involves the backward displacement of one or both mitral valve leaflets during systole, potentially leading to regurgitation. While the aortic root in MASS syndrome may be dilated, it typically remains within the upper normal range and does not exhibit the progressive enlargement seen in Marfan syndrome.

Striae distensae are common and can occur independently of significant growth spurts, indicating altered dermal elasticity. Skeletal features, while overlapping with Marfan syndrome, are generally milder and may include joint hypermobility, pectus deformities, scoliosis, and arachnodactyly (long, slender fingers).

Distinguishing MASS syndrome from Marfan syndrome and other fibrillinopathies is critical for accurate management. Both conditions arise from FBN1 mutations, but key differences exist. Crucially, individuals with MASS syndrome typically do not develop the progressive aortic root dilatation that poses a significant risk of dissection or rupture in Marfan syndrome.

Furthermore, lens dislocation, a hallmark of Marfan syndrome, is generally absent in MASS syndrome. The skeletal manifestations in MASS syndrome are also typically less severe. This nuanced understanding guides clinical surveillance and therapeutic strategies, emphasizing the importance of detailed phenotypic assessment alongside genetic testing.

The FBN1 gene is located on chromosome 15 and comprises 65 exons. It encodes fibrillin-1, a major component of extracellular microfibrils. These microfibrils are essential structural elements that provide mechanical support and also sequester growth factors, notably TGF-β (transforming growth factor-beta).

Mutations in FBN1 can lead to reduced fibrillin-1 production, impaired assembly into functional microfibrils, or the production of abnormal fibrillin-1 that may interfere with normal microfibril function. The precise impact of a specific FBN1 mutation on the resulting phenotype is complex and influenced by factors such as the mutation's location, the type of mutation (e.g., missense, nonsense, deletion), and potentially other genetic modifiers. The dysregulation of TGF-β signaling, secondary to microfibril dysfunction, is thought to contribute significantly to the cardiovascular and skeletal manifestations.

Management of MASS syndrome is primarily symptomatic and requires a multidisciplinary approach. Cardiovascular monitoring is essential, focusing on regular echocardiographic assessment of the aortic root diameter to detect any significant dilatation, although the risk is generally lower than in Marfan syndrome. Prophylactic beta-blocker therapy or ARBs may be considered in select cases to reduce mechanical stress on the aorta.

Skeletal issues like scoliosis and pectus deformities may require orthopedic intervention. Regular ophthalmological evaluations are recommended, though lens dislocation is rare. Future research may focus on understanding the precise molecular mechanisms underlying the phenotypic variability and exploring targeted therapies that could modulate TGF-β signaling or enhance fibrillin-1 function, potentially offering more definitive treatment options.